Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength

Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength

Jazz is doing well selling its specialty drugs including blockbuster narcolepsy drug Xyrem. The new rating means that Jazz has outperformed 81% of all stocks in the S&P 500 on key metrics over the past year. Jazz Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Ethical Drugs industry group.